{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:06Z","timestamp":1790409246766,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01802-w","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:55:41Z","timestamp":1776884141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in multiple myeloma: key updates from the ASH 2025 meeting"],"prefix":"10.1186","volume":"19","author":[{"given":"Phyu Thin","family":"Naing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-8458","authenticated-orcid":false,"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"suppl 1","key":"1802_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1182\/blood-2025-248","volume":"146","author":"D Kazandjian","year":"2025","unstructured":"Kazandjian D, Diamond B, Hoffman J, et al. A phase 2 trial of abbreviated fixed-duration (default 4 cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study). Blood. 2025;146(suppl 1):248\u20139. https:\/\/doi.org\/10.1182\/blood-2025-248.","journal-title":"Blood"},{"issue":"suppl 1","key":"1802_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2025-367","volume":"146","author":"S Manier","year":"2025","unstructured":"Manier S, Lambert J, Macro M, et al. A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 TECLILLE trial, cohort A. Blood. 2025;146(suppl 1):367\u20138. https:\/\/doi.org\/10.1182\/blood-2025-367.","journal-title":"Blood"},{"issue":"suppl 1","key":"1802_CR3","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2025-LBA-6","volume":"146","author":"MV Mateos","year":"2025","unstructured":"Mateos MV, Bahlis N, Perrot A, et al. Teclistamab plus daratumumab versus daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma: MajesTEC-3 phase 3 study results. Blood. 2025;146(suppl 1):LBA\u20136. https:\/\/doi.org\/10.1182\/blood-2025-LBA-6.","journal-title":"Blood"},{"key":"1802_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Bahlis NJ, Perrot A, et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2514663.","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"1802_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2025-100","volume":"146","author":"A Suvannasankha","year":"2025","unstructured":"Suvannasankha A, Kaufman J, Badros A, et al. Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: results from the phase 1b MagnetisMM-30 trial. Blood. 2025;146(suppl 1):100\u20131. https:\/\/doi.org\/10.1182\/blood-2025-100.","journal-title":"Blood"},{"issue":"10","key":"1802_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29(10):2570\u20136. https:\/\/doi.org\/10.1038\/s41591-023-02589-w.","journal-title":"Nat Med"},{"issue":"suppl 1","key":"1802_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1182\/blood-2025-698","volume":"146","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Cohen YC, Kumar S, et al. Talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma and extramedullary disease: extended follow-up from the RedirecTT-1 study. Blood. 2025;146(suppl 1):698. https:\/\/doi.org\/10.1182\/blood-2025-698.","journal-title":"Blood"},{"issue":"1","key":"1802_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2514752","volume":"394","author":"S Kumar","year":"2026","unstructured":"Kumar S, Mateos MV, Ye JC, et al. Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab. N Engl J Med. 2026;394(1):51\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2514752.","journal-title":"N Engl J Med"},{"issue":"9","key":"1802_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.clml.2025.03.014","volume":"25","author":"P Moreau","year":"2025","unstructured":"Moreau P, Mateos MV, Goldschmidt H, et al. Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies. Clin Lymphoma Myeloma Leuk. 2025;25(9):646\u2013e6551. https:\/\/doi.org\/10.1016\/j.clml.2025.03.014.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 2","key":"1802_CR10","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2025-LBA-1","volume":"146","author":"S Harrison","year":"2025","unstructured":"Harrison S, Ho PJ, Lim SL, et al. Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood. 2025;146(suppl 2):LBA\u20131. https:\/\/doi.org\/10.1182\/blood-2025-LBA-1.","journal-title":"Blood"},{"issue":"4","key":"1802_CR11","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34(4):1197\u2013201. https:\/\/doi.org\/10.1038\/s41375-019-0620-8.","journal-title":"Leukemia"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01802-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01802-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01802-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:55:42Z","timestamp":1776884142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01802-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1802"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01802-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The current work was exempted from requiring Ethics approval and consent to participate based on institutional guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"MB reports Consultancy: AbbVie, J&J, Sanofi-Genzyme; Advisory Boards: Janssen Biotech, J&J, Sanofi-Genzyme, Pfizer, Prothena, AbbVie, Legend Biotech; Research Grants: Pfizer, J&J; Scientific Advisory Board seat: Xilis Inc.; DSMB: Delta-Fly; IRCs: Parexel International. PTN reports no financial conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"27"}}